Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4648 - Prospective Observational Cohort study of Oesophagogastric cancer Patients (POCOP): a Dutch nationwide cohort


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site

Gastric Cancer


Jessy Joy van Kleef


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


J.J. van Kleef1, L.V. van de Poll-Franse2, R.H. Verhoeven3, M. Slingerland4, J.P. Ruurda5, J. Heisterkamp6, C. Rosman7, J.W.B. de Groot8, E.A. Kouwenhoven9, M.A. van Dijk10, E. de Graaf11, T. van Voorthuizen12, F. Daams13, S. Lagarde14, G.A.P. Nieuwenhuijzen15, J. Vincent16, M. van Berge Henegouwen17, M.G.H. van Oijen1, M.A.G. Sprangers18, H.W.M. van Laarhoven19

Author affiliations

  • 1 Department Of Medical Oncology, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 2 Department Of Psychosocial Research And Epidemiology, The Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 3 Department Of Research, Netherlands Comprehensive Cancer Organisation, 3511 DT - Utrecht/NL
  • 4 Department Of Medical Oncology, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 5 Department Of Surgery, University Medical Center Utrecht, Utrecht/NL
  • 6 Department Of Surgery, Elisabeth-Tweesteden Hospital, Tilburg/NL
  • 7 Department Of Surgery, Radboud University Medical Center, Nijmegen/NL
  • 8 Department Of Medical Oncology, Isala Hospital, Zwolle/NL
  • 9 Department Of Surgery, HospitalGroup Twente (ZGT), Almelo/NL
  • 10 Department Of Medical Oncology, ZorgSaam Hospital, Terneuzen/NL
  • 11 Department Of Medical Oncology, Reinier de Graaf Hospital, Delft/NL
  • 12 Department Of Medical Oncology, Rijnstate Hospital, Arnhem/NL
  • 13 Department Of Surgery, VU Medical Center, Amsterdam/NL
  • 14 Department Of Surgery, Erasmus Medical Center, Rotterdam/NL
  • 15 Department Of Surgery, Catharina Cancer Institute, Catharina Hospital, Eindhoven/NL
  • 16 Department Of Medical Oncology, Elkerliek Hospital, 5707 HA - Helmond/NL
  • 17 Department Of Surgery, Academic Medical Center, Amsterdam/NL
  • 18 Department Of Medical Psychology, Academic Medical Center (AMC), Amsterdam/NL
  • 19 Department Of Medical Oncology, Academic Medical Center (AMC), 1100 DD - Amsterdam/NL


Abstract 4648


POCOP is a novel prospective scientific database including oesophagogastric cancer patients, initiated by the Dutch Upper GI Cancer Group (DUCG) to stimulate multidisciplinary research. Within POCOP treatment and diagnostic strategies as well as prognostic and predictive factors for outcome can be evaluated on a population-based level. We present the design and current proceedings.


All patients with oesophagogastric cancer in the Netherlands are eligible. Patients need to provide consent for: 1) the reuse of clinical data collected by the Netherlands Cancer Registry (NCR), 2) longitudinal collection of patient reported outcomes (PROs), receiving future information on new interventional studies (including cohort multiple randomized controlled trials (cmRCT)), and/or 3) linkage with Dutch databases e.g. the Dutch Upper GI Cancer Audit, the biobank of The Parelsnoer Institute and general practitioner databases. Funding: Dutch Cancer Society (UVA 2014-7000).


Thus far, clinical data is being collected from almost all Dutch patients with oesophagogastric cancer diagnosed from 2015 onwards. Clinical data mainly consist of patient, tumour and multidisciplinary sequential treatment characteristics. The collection of longitudinal PROs started in 2016. Of all patients who gave consent (N = 1000), 92% also participated in the PRO-registry. PRO compliance was 87%, 67% and 46% (not accounted for death or drop-out) at diagnosis, 3 and 6 months follow-up, respectively. 81% of patients consented to receive future information on new interventional studies, including cmRCTs. Collaborations with phase II/III trials and other cohort studies were established to reduce patient burden regarding completion of PROs and trial registration burden. Obtained data is governed by the DUCG scientific committee which includes members of participating hospitals, the study team and the NCR.


POCOP provides real world population-based data to stimulate (inter-)national multidisciplinary research and provides the opportunity to perform novel trials within the established infrastructure. Researchers can acquire data by submitting a research proposal to the scientific committee of the DUCG (www.ducg.nl).

Clinical trial identification

Legal entity responsible for the study

Dutch Upper GI Cancer Group.


Dutch Cancer Society.

Editorial Acknowledgement


J.W.B. de Groot: Advisory role: BMS and MSD. T. van Voorthuizen: Travel, accomodations, expenses: Ipsen, Astellas M. van Berge Henegouwen: Consulting/advisory: Olympus, Covidien; Research funding: Olympus; Travel, accomodations, expenses: Johnson&Johnson M.G.H. van Oijen: Research funding: Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Roche. H.W.M. van Laarhoven: Consultancy: Celgene, Lilly, Nordic. Research funding: Bayer, Lilly, Merck Serono, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.